Oral Anticoagulant Therapy in Patients with Peripheral Artery Disease

Seminars in Vascular Medicine

Volumn 3, Issue 3, 2003, Pages 339-344

  Visseren, F L J ^a   Eikelboom, B C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiovascular risk reduction; Oral anticoagulants; Peripheral artery disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; WARFARIN;

ANTICOAGULATION; ARTERY BYPASS; ARTERY DISEASE; ARTERY OCCLUSION; DRUG EFFICACY; GRAFT OCCLUSION; HUMAN; INTERMITTENT CLAUDICATION; INTERNATIONAL STANDARD UNIT; LIMB ISCHEMIA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; RISK ASSESSMENT; VEIN GRAFT;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR DISEASES; HUMANS; PERIPHERAL VASCULAR DISEASES; VASCULAR SURGICAL PROCEDURES; WARFARIN;

EID: 0142040236     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-44470     Document Type: Review

References (24)

1. Leng GC, Fowkes FGR, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Br Med J 1996;313:1440-1444
2. Criqui MH, Langer MD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-386
3. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T. Fate in intermittent claudication: outcome and risk factors. Br Med J 1986;293:1137-1140
4. Donnelly R, Yeung JM. Management of intermittent claudication: the importance of secondary prevention. Eur J Vasc Endovasc Surg 2002;23:100-107
5. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81:333-335
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
7. Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev 2001;3: CD001999
8. Dettori AG, Pini M, Moratti A, et al. Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group. Angiology 1989;40:237-248
9. De Smit P, van Urk H. Dutch oral anticoagulation trial. Act Chir Austr 1992;24:5-7
10. Antithrombotic Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106
11. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis or randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86
12. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339
13. Blaisdell FW, Steele M, Allen RE. Management of acute lower extremity arterial ischemia due to embolism and thrombosis. Surgery 1978;84:822-834
14. Tasc Working Group. Management of peripheral arterial disease (PAD). J Vasc Surg 2000;31:s205-s226
15. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994;308:159-168
16. The Femoro-Popliteal Bypass Trial Participants, Aspirin usage and its influence on femoro-popliteal vein graft patency. Eur J Vasc Surg 1992;6:185-188
17. Kretschmer G, Herbst F, Prager M, et al. A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 1992;127:1112-1115
18. Kretschmer G, Wenzl E, Piza F, et al. The influence of anticoagulant treatment on the probability of function in femoropopliteal vein bypass surgery: analysis of a clinical series (1970 to 1985) and interim evaluation of a controlled clinical trial. Surgery 1987;102:453-459
19. Kretschmer G, Wenzl E, Schemper M, et al. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. Lancet 1988;I:797-799
20. Dutch Bypass Oral Anticoagulants or Aspirin (BOA) study group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal by ass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial. Lancet 2000;355:346-351
21. Johnson WC, Williford WO, members of the Department of Veterans Affairs Cooperative Study #362. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomised study. J Vasc Surg 2002;35:413-421
22. Arfvidson B, Lundgren F, Drott C, Schersen T, Lundholm K. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg 1990;159:556-560
23. Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, Seeger JM. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998;28:446-457
24. Schneider E, Brunner U, Bollinger A. Medikamentöse Rezidivprophylaxe nach femoropoplitealer Arterienrekonstruktion. Angio 1979;2:73-77